相关实验视频

Updated: Mar 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

较薄的支架设计对当前一代药物排泄支架在全新手中的影响

Thierry Witzig¹, Serban Puricel¹, Alain Witzig¹

¹Cardiology, University & Hospital Fribourg, Switzerland.

Cardiovascular revascularization medicine : including molecular interventions

|March 4, 2026

概括

在两年内,薄支架药物排泄支架 (DES) 与厚支架DES相比,显著降低了面向设备的复合终点 (DOCE). 这项研究强调了更薄的支架设计在真实世界皮肤穿透冠状动脉干预结果中的好处.

科学领域:

心血管医学心血管医学
干预心脏病学干预心脏病学
生物医学工程生物医学工程

背景情况:

自2002年以来,药物排泄支架 (DES) 取得了显著的进步.
目前的研究重点是通过更薄的支架设计来改进DES平台.
这项研究评估了当前一代DES的现实结果,其杆厚度各不相同.

研究的目的:

为了比较薄 (≤80微米) 和厚 (>80微米) 支架之间的临床结果,DES.
评估更薄的支架设计对皮肤穿冠状动脉干预 (PCI) 成功的影响.
分析面向设备的复合终点 (DOCE) 的两年发生率.

主要方法:

从心脏FR数据库中分析了2551名接受PCI的患者.
纳入标准侧重于接受薄或厚支架DES的患者,并对其进行为期两年的随访.
主要结局:DOCE (心脏死亡,目标血管心肌梗塞,目标病变再血管化).

主要成果:

在多变量调整后,厚型杆DES显示较高的2年DOCE率与薄型杆DES相比 (调整的OR:1.298;p=0.045).
发生中风事件的频率较小,使用厚型杆DES (2.0%对3.4%;p=0.041).
在两组之间的其他事件率中没有发现显著差异.

结论:

在两年后的随访中,薄型杆DES与厚型杆DES相比,与明显较低的DOCE率有关.
这些发现支持在现实PCI中更薄的支架支架设计的临床益处.
进一步的研究是有必要的,以充分阐明在DES中更薄的支架技术的性能影响.

关键词:

在 DOCE DOCE 里面.药物释放的支架可以释放药物.通过皮肤进行冠状动脉干预.薄薄的支架可以支.赢得比率的比率是什么

更多相关视频

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis

Published on: January 21, 2020

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention

Published on: September 18, 2015

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...